Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Benzodiazepines and dementia

Benzodiazepines and dementia

Can benzodiazepines increase the risk for dementia? Researchers in France studied 1063 men and women with an average age of 78 who were free of dementia and did not start taking benzodiazepines until they had been followed for at least 3 years. During a 15-year follow-up, 253 cases of dementia were confirmed. New use of benzodiazepines occurred in 9% of the study population and was associated with an increased risk of dementia (32% benzodiazepine group vs 23%, adjusted hazard ratio 1.60, 95% confidence interval [CI] 1.08-2.38). After correcting for the existence of depressive symptoms as well as age and diabetes, the hazard ratio was unchanged. A secondary analysis looking at participants who started benzodiazepines at different times during follow-up also showed an elevated risk of dementia. Results of the complementary, nested, case-control study showed that ever use of benzodiazepines was associated with an approximate 50% increased risk of dementia compared with never users. The authors conclude that in this prospective, population-based study new use of benzodiazepines was associated with a significantly increased risk of dementia. They further conclude that "indiscriminate widespread use should be cautioned against" (BMJ 2012;345:e6231). The obvious criticism of the study was the presence of confounders — whether use of benzodiazepines was a marker for early onset dementia rather than a cause. While the authors feel the study was carefully controlled, selection bias cannot be completely ruled out. They further state that the research should be done on younger patients to see if starting benzodiazepines at ages younger than 65 may have deleterious effects. They also recommend that "physicians and regulatory agencies should consider the increasing evidence of potential adverse effects of this drug class for the general population."